Teriflunomide attenuates immunopathological changes in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

被引：35

作者：

Ringheim, Garth E. ^{[1
]}

Lee, Lan ^{[2
]}

Laws-Ricker, Lynn ^{[3
]}

Delohery, Tomas ^{[4
]}

Liu, Li ^{[5
]}

Zhang, Donghui ^{[5
]}

Colletti, Nicholas ^{[6
]}

Soos, Timothy J. ^{[6
]}

Schroeder, Kendra ^{[7
]}

Fanelli, Barbara ^{[7
]}

Tian, Nian ^{[8
]}

Arendt, Christopher W. ^{[6
]}

Iglesias-Bregna, Deborah ^{[9
]}

Petty, Margaret ^{[10
]}

Ji, Zhongqi ^{[11
]}

Qian, George ^{[6
]}

Gaur, Rajula ^{[12
]}

Weinstock, Daniel ^{[13
]}

Cavallo, Jean ^{[12
]}

Telsinskas, Juventas ^{[14
]}

McMonagle-Strucko, Kathleen ^{[10
]}

机构：

[1] Celgene Corp, Inflammat & Immunol Translat Dev, 86 Morris Ave, Summit, NJ 07901 USA

[2] Sanofi Genzyme R&D Ctr, Tissue Protect & Repair, Bridgewater, NJ USA

[3] Sanofi, Neuroimmunol, Framingham, MA USA

[4] Merck Res Labs, Mol Biomarkers, Flow Cytometry, Boston, MA USA

[5] Sanofi, Global Biostat & Programming, Clin Sci & Operat, Bridgewater, NJ USA

[6] Sanofi, BioTherapeut, Bioinnovat, Cambridge, MA USA

[7] Sanofi, TSU Immuno Inflammat, Target & Syst Immunol Inst, Bridgewater, NJ USA

[8] Sanofi, Clin Sci & Operat, Clin Exploratory Pharmacol, Bridgewater, NJ USA

[9] Lundbeck Res USA Inc, Bioanal Physiol, Electrophysiol Pharmaco EEG, Paramus, NJ USA

[10] Sanofi, Immunoinflammat, Expt Pharmacol Neurol, Bridgewater, NJ USA

[11] Sanofi, Med Operat, Coding Grp, Bridgewater, NJ USA

[12] Sanofi Genzyme R&D Ctr, Proteogenom Genet & Genom, Mol Histol & Appl Imaging, Bridgewater, NJ USA

[13] Janssen Res & Dev LLC, Biol Ctr Excellence, Immunotoxicol & Expt Pathol, Biol Toxicol, Spring House, PA USA

[14] Sanofi, Biol Discovery, Phage Display, Framingham, MA USA

来源：

FRONTIERS IN NEUROLOGY | 2013年 / 4卷

关键词：

multiple sclerosis; teriflunomide; experimental autoimmune encephalomyelitis; lymphocytes; dihydro-orotate dehydrogenase;

D O I：

10.3389/fneur.2013.00169

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.

引用

页数：12

共 57 条

[1] Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool [J].

Ajami, Bahareh ;

Bennett, Jami L. ;

Krieger, Charles ;

McNagny, Kelly M. ;

Rossi, Fabio M. V. .

NATURE NEUROSCIENCE, 2011, 14 (09) :1142-U263

[2] CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis [J].

Bai, XF ;

Li, O ;

Zhou, QM ;

Zhang, HM ;

Joshi, PS ;

Zheng, XC ;

Liu, Y ;

Wang, Y ;

Zheng, P ;

Liu, Y .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (04) :447-458

[3] Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis [J].

Bar-Or, Amit ;

Freedman, Mark S. ;

Kremenchutzky, Marcelo ;

Menguy-Vacheron, Francoise ;

Bauer, Deborah ;

Jodl, Stefan ;

Truffinet, Philippe ;

Benamor, Myriam ;

Chambers, Scott ;

O'Connor, Paul W. .

NEUROLOGY, 2013, 81 (06) :552-558

[4] The pathology of multiple sclerosis: a paradigm shift [J].

Barnett, Michael H. ;

Sutton, Ian .

CURRENT OPINION IN NEUROLOGY, 2006, 19 (03) :242-247

[5] Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease [J].

Bjartmar, C ;

Wujek, JR ;

Trapp, BD .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) :165-171

[6] Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide [J].

Bruneau, JM ;

Yea, CM ;

Spinella-Jaegle, S ;

Fudali, C ;

Woodward, K ;

Robson, PA ;

Sautès, C ;

Westwood, R ;

Kuo, EA ;

Williamson, RA ;

Ruuth, E .

BIOCHEMICAL JOURNAL, 1998, 336 :299-303

[7] The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease [J].

Carlson, Thaddeus ;

Kroenke, Mark ;

Rao, Praveen ;

Lane, Thomas E. ;

Segal, Benjamin .

JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (04) :811-823

[8]

CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V275, P1043

[9]

CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V272, P460

[10] Immune mechanisms of new therapeutic strategies in MS - Teriflunomide [J].

Claussen, Malte C. ;

Korn, Thomas .

CLINICAL IMMUNOLOGY, 2012, 142 (01) :49-56

← 1 2 3 4 5 6 →